Drug Profile
Research programme: apoptosis targeted therapy - Aposense
Alternative Names: Aposense Targeted Therapy; ATT-GEM; ATT-LDLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aposense
- Developer Aposense; Teva Pharmaceutical Industries
- Class Antineoplastics; Drug conjugates; Small molecules
- Mechanism of Action DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (PO)
- 01 Sep 2012 Preclinical trials in Parkinson's disease in Israel (PO)